Reviewing Absci (ABSI) & Its Peers

Absci (NASDAQ:ABSI – Get Rating) is one of 40 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare Absci to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

40.0% of Absci shares are held by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are held by institutional investors. 11.4% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Absci and its peers gross revenue, earnings per share (EPS) and valuation.

Gross revenue Net Income Price/earnings ratio
absci $4.78 million -$100.96 million -1.16
Absci Competitors $2.80 billion $97.54 million 13.51

Absci’s peers have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

profitability

This table compares Absci and its peers’ net margins, return on equity and return on assets.

net margins return on equity return on assets
absci -2,633.14% -36.19% -22.99%
Absci Competitors -260.35% -8.17% -2.92%

Analyst Ratings

This is a summary of current ratings and price targets for Absci and its peers, as provided by MarketBeat.com.

sell ratings hold ratings Buy rating Strong Buy Ratings rating score
absci 1 3 3 0 2.29
Absci Competitors 105 773 1306 30 2.57

Absci currently has a consensus target price of $24.00, indicating a potential upside of 520.16%. As a group, “Commercial physical research” companies have a potential upside of 39.12%. Given Absci’s higher possible upside, equities analysts clearly believe Absci is more favorable than its peers.

Summary

Absci peers beat Absci on 11 of the 12 factors compared.

About Absci (Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Receive News & Ratings for Absci Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Absci and related companies with MarketBeat.com’s FREE daily email newsletter.